Abstract
Severe neutropenia is associated with radiation therapy when large areas of bone marrow are exposed and more often associated with concurrent chemoradiotherapy, which can cause treatment unplanned interruptions and may compromise clinical outcome (e.g., decreased local control rate of head-and-neck cancers). An orally-active neutrophil stimulant which reduces the duration or magnitude of neutropenia would benefit patients undergoing radiation therapy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have